Oligonucleotide Therapeutics Market 2022 Global Projection By Key Players - PCI Biotech, SomaGenics, ContraVir, Alnylam, Regulus Therapeutics- Analysis and Forecast to 2024

Oligonucleotide Therapeutics Market 2022

Oligonucleotides are short chain RNA or DNA which are usually manufactured by utilizing automated synthesizers. Purification of the oligonucleotide is done by anion exchange chromatography which is followed by desalting and freezing technique. For the synthesis of siRNA duplex oligonucleotide, an annealing step is carried out where two purified oligonucleotide strands are brought together in an equimolar ratio.

Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/12787

Oligonucleotide therapeutics are different from conventional medicine as they can inhibit the expression of certain genes. This has given rise to innovative new oligonucleotides that can target specific genes and treat chronic diseases. The development of oligonucleotide therapeutics is done through chemically modified artificial nucleic acids. The artificial oligonucleotides are being developed which has improved in vivo stability and enhanced affinity to target mRNA.

The demand for oligonucleotides is expected to upsurge as there are very few approved molecules. This has offered oligonucleotide market players a wide scope to discover new molecular entities. Moreover, the technology upgrades of chemically synthesized oligonucleotides have led to the development of more stable and extended half-life molecules.

There are around 135 oligonucleotide therapeutics currently in different stages of drug development, which may further add to the limited three approved drugs currently available in the oligonucleotide therapeutics market.

Oligonucleotide Therapeutics Market: Segmentation

On the basis of application
Infectious diseases
Oncology
Neurodegenerative disorders
Cardiovascular diseases
Kidney diseases
Others

On the basis of type
Antisense
Ribozymes
Aptamers
miRNA
CpG/Immunostimulatory
RNAi

Request for Table of Content@ https://www.persistencemarketresearch.com/toc/12787

The presence of the main market leaders, market consolidation and commercialization of new molecules are all contributing towards the dominating position of North America in the oligonucleotides therapeutic market. Miragen Therapeutics, Inc. agreed to merge with Signal Genetics, Inc for an initial investment of USD 40 million. Through this merger both the companies expect to develop micro RNA-targeted oligonucleotide clinical products.

New molecule application is also another strategy the market players are using to mark their presence in the oligonucleotide therapeutic market. Biogen recently received FDA approval for a new drug application for nusinersen. If approved, the antisense oligonucleotides molecule would be the first of its kind to be used for treating spinal muscular atrophy.

Asia-Pacific is the fastest growing region as several oligonucleotide therapeutics manufacturers are looking forward to establishing manufacturing facilities in this region. Moreover, research undertaking and funding in the synthesis of oligonucleotides are expected to add on to the increasing demand.

Recently, Daiichi Sankyo Co., Ltd. announced its intention to open up a new company named Orphan Disease Treatment Institute Co., Ltd. to treat Duchenne muscular dystrophy through its active ingredient ENA oligonucleotide. The company is a collaboration between Daiichi, Mitsubishi UFJ Capital Co., Ltd. and Innovation Network Corporation of Japan and looks forward to entering the oligonucleotide therapeutics market.

One of the major trends driving the oligonucleotides therapeutic market is the increasing licensing and collaboration activities. Moreover, the demand for advanced technologies in oligonucleotide therapeutics such as gene silencing through RNAi is gaining importance due to its high efficiency, thereby propelling the oligonucleotide therapeutics market.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/12787

Some of the key contributors to the oligonucleotide therapeutics market are PCI Biotech, SomaGenics, ContraVir, Alnylam, Regulus Therapeutics, Ionis Pharmaceuticals, Gilead, Santaris, InteRNA, miRage, Biogen, Merck and Pfizer, among others.

Key Questions Answered in the Oligonucleotide Therapeutics Market Report

How is the Oligonucleotide Therapeutics Market expected to grow over the projected period?

What direction is the Oligonucleotide Therapeutics Market expected to take in terms of volume and value during the forecast period?

What is the impact of macroeconomic factors on the Oligonucleotide Therapeutics Market in future?

What are the key market drivers in the Oligonucleotide Therapeutics Market?

What are significant opportunities and improvement areas for Oligonucleotide Therapeutics Market manufacturers?

What are the key developments and trends taking over the Oligonucleotide Therapeutics Market?

Which are the emerging countries that are expected to create significant growth opportunities in the Oligonucleotide Therapeutics Market?  

Read Also- 

MRI Systems Market - https://www.persistencemarketresearch.com/market-research/mri-systems-market.asp

Functional Brain Imaging Systems Market - https://www.persistencemarketresearch.com/market-research/functional-brain-imaging-systems-market.asp

Contact Us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About Us: 

PersistenceMarketResearch is an esteemed company with a reputation of serving clients across domains of information technology (IT), healthcare, and chemicals. Our analysts undertake painstaking primary and secondary research to provide a seamless report with a 360 degree perspective. Data is compared against rep/uted organizations, trustworthy databases, and international surveys for producing impeccable reports backed with graphical and statistical information.

This release was published on openPR.